Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30 mg m(−2) intravenous (i.v.), weekly, plus estramustine 280 mg twice daily for 12 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Galli, L, Fontana, A, Galli, C, Landi, L, Fontana, E, Antonuzzo, A, Andreuccetti, M, Aitini, E, Barbieri, R, Di Marsico, R, Falcone, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360275/
https://www.ncbi.nlm.nih.gov/pubmed/18026196
http://dx.doi.org/10.1038/sj.bjc.6604090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360275/
https://www.ncbi.nlm.nih.gov/pubmed/18026196
http://dx.doi.org/10.1038/sj.bjc.6604090

Ejemplares similares